Recro Pharma, Inc. (NASDAQ:REPH) major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $9.50, for a total value of $973,180.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Friday, November 24th, Healthcare Master Fun Broadfin sold 172,208 shares of Recro Pharma stock. The shares were sold at an average price of $9.45, for a total value of $1,627,365.60.

Shares of Recro Pharma, Inc. (NASDAQ REPH) remained flat at $$9.38 during mid-day trading on Friday. The company’s stock had a trading volume of 67,239 shares, compared to its average volume of 80,071. Recro Pharma, Inc. has a 12-month low of $5.81 and a 12-month high of $10.17. The company has a current ratio of 1.59, a quick ratio of 1.35 and a debt-to-equity ratio of 0.50.

A number of hedge funds have recently modified their holdings of the stock. Alyeska Investment Group L.P. raised its holdings in Recro Pharma by 3.4% during the third quarter. Alyeska Investment Group L.P. now owns 906,398 shares of the specialty pharmaceutical company’s stock worth $8,139,000 after purchasing an additional 29,799 shares during the last quarter. Wells Fargo & Company MN grew its position in Recro Pharma by 42.5% during the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock valued at $220,000 after acquiring an additional 7,308 shares during the period. Cadence Capital Management LLC grew its position in Recro Pharma by 34.7% during the third quarter. Cadence Capital Management LLC now owns 167,637 shares of the specialty pharmaceutical company’s stock valued at $1,505,000 after acquiring an additional 43,146 shares during the period. JPMorgan Chase & Co. grew its position in Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after acquiring an additional 14,098 shares during the period. Finally, Essex Investment Management Co. LLC grew its position in Recro Pharma by 40.3% during the third quarter. Essex Investment Management Co. LLC now owns 93,199 shares of the specialty pharmaceutical company’s stock valued at $837,000 after acquiring an additional 26,785 shares during the period. 64.97% of the stock is owned by hedge funds and other institutional investors.

Several analysts have recently commented on the company. Zacks Investment Research cut Recro Pharma from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Piper Jaffray Companies reissued a “buy” rating and issued a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. Finally, Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Monday, July 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $12.88.

COPYRIGHT VIOLATION NOTICE: “Recro Pharma, Inc. (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 102,440 Shares of Stock” was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.watchlistnews.com/recro-pharma-inc-reph-major-shareholder-healthcare-master-fun-broadfin-sells-102440-shares-of-stock/1726192.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

Insider Buying and Selling by Quarter for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.